NEW YORK (AP) _ Stemline Therapeutics Inc. (STML) on Friday reported a loss of $26.6 million in its fourth quarter.
The New York-based company said it had a loss of 92 cents per share.
The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 72 cents per share.
For the year, the company reported that its loss widened to $85 million, or $2.99 per share. Revenue was reported as $500,000.
Stemline Therapeutics shares have climbed 43 percent since the beginning of the year. In the final minutes of trading on Friday, shares hit $13.62, a drop of 9 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on STML at https://www.zacks.com/ap/STML